Prolight Diagnostics has received SEK 17 million (~USD 16.1 million) as a grant from the i4i Product Development Awards sponsored by the National Institute for Health and Care Research, UK.

The funds are expected to support a pre-validation study at St. Thomas’ Hospital to evaluate the performance of the company’s Psyros point-of-care test for cardiac arrest before the clinical trials in 2025.

Sweden-based Prolight Diagnostics specializes in developing point-of-care systems for in-vitro diagnostic (IVD) testing. Its flagship technology, Psyros, is a digital immunoassay platform capable of single-molecule counting. It is primarily used to detect cardiac biomarkers like troponin, with future applications in development for other biomarkers. Psyros allows the detection of low levels of troponin, released into the bloodstream during a heart attack, for early detection of heart attacks and prioritizing patients according to criticality.